comprehensive -WSS

comprehensive

author：focus 2025-10-04 06:00:59 - browse：5394

Medicare and money photo illustration. — Adobe

Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier.

CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

“I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Neuroscience startup Neumora files for IPO

knowledge

WSS

Departing Stanford president retracts two papers

Unique patient identifier: Experts argue the benefits, pitfalls

Study finds new variant for Parkinson’s in African populations

AstraZeneca stays mum on Medicare drug pricing negotiations

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Readout LOUD: Venture capital, Gilead, and more M&A

knowledge

comprehensive

Wikipedia

Alkermes shareholders re

How Long Island became the ‘eugenics capital of the world’

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

2024 GOP presidential candidates spar over abortion in debate

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In science, is the line between industry and academia shifting?

Affirmative action in medical school literally saved lives

The Biogen Aduhelm mess could happen again

explore

The CDC's new social media misinformation war

Apellis safety probe of eye disease drug centers on injection needle

FDA panel gives mixed vote on blood pressure devices

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

A single Democrat is willing to weaken Medicare negotiation power

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

entertainment

leisure time

knowledge

knowledge